<DOC>
	<DOCNO>NCT01919866</DOCNO>
	<brief_summary>Feasibility toxicity haploidentical transplantation CD3/CD19 deplete stem cell combination toxicity reduce condition regimen standard conditioning regimen accord underlying disease .</brief_summary>
	<brief_title>Safety Study CD3/CD19 Depleted Haploidentical Stem Cells</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>patient primary refractory relapse disease ( include relapse previous SCT active disease ) AML complete remission refractory MDS RAEBt/secondary AML ALL CML NonHodgkin Lymphoma / Hodgkin Lymphoma non malignant disease ( aplastic anemia , thalassemia , SCID ) relapse Neuroblastoma relapse soft tissue sarcoma ( Rhabdomyosarcoma , Ewing sarcoma , PNET soft tissue sarcoma primary bone metastases bone marrow match donor available , &lt; 6 month previous HSCT active cerebral seizure condition massive progression leukemia solid tumour plan trp . leave ventricular ejection fraction &lt; 25 % creatinine clearance &lt; 40ml/min condition respiratory insufficiency oxygen demand DLCO &lt; 30 % Bilirubin &gt; 4mg/dl , GOT/GPT &gt; 400 severe infection ( HIV , Aspergillosis ) pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>